Journal
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
Volume 18, Issue 2, Pages 146-153Publisher
WILEY
DOI: 10.1111/1756-185X.12490
Keywords
biologics; immunotherapy; lupus; monoclonal antibodies; systemic lupus erythematosus; targeted therapies
Categories
Ask authors/readers for more resources
Significant progress has been made in the development of therapies for systemic lupus erythematosus (SLE). These include agents which target interferons, cytokines, T lymphocytes and co-stimulatory molecules, B-lymphocytes and B stimulatory molecules. The latter are of special interest having the most robust efficacy data to date, ranging from clinical experience to clinical trials, with belimumab as the first Food and Drug Administration-approved biologic for the treatment of SLE. Given the wide disease heterogeneity, certain issues like clinical trial design and pharmacogenomics will continue to challenge drug development in SLE, there will always be a growing and compelling need for more of these drugs in order to alleviate the burden of illness in lupus patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available